Adelaide, Australia | North Carolina, USA – Avance Clinical, the Australian and North American market-leading CRO for biotechs, has signed a strategic technology MOU with leading Korean decentralized clinical trials (DCTs) and eClinical technology company JNPMEDI Inc. The agreement expands Avance Clinical’s capabilities in the Asia-Pacific biotech clinical trials sector.
Anne Sim, Associate Director, Technology, and Innovation said, “Avance Clinical is focused on growing our networks with technology companies which offer high-quality innovative solutions designed to further accelerate the delivery of quality data to our biotech clients.
As we continue to invest in digital capacity, JNPMEDI is one company we are exploring. They are also located within the important Asia-Pacific region which really helps that relationship.”
Upon signing the MOU, Jae Hyun Lee J.D., D.D.S., Chief of Staff at JNPMEDI, expressed, “JNPMEDI is excited to partner with Avance Clinical. Korea biotech industry is an exciting and growing one, and one whose needs are uniquely answered by Avance Clinical and the Australian clinical trial market. The partnership will provide a turnkey answer to the biotech market.”
JNPMEDI’s core technology is Maven Clinical Cloud which offers a singular ecosystem for digital clinical solutions capable of streamlining activities from protocol to CSR. This ‘one stop shop’ supports subject participation while delivering efficiencies to study sites, sponsors and CROs.
The Avance Clinical Technology and Innovation team identifies and reviews the latest technology solutions including machine learning and artificial intelligence applications to support global systems integrations.
JNPMEDI and Avance Clinical connected recently at the KoNECT Korea conference in Seoul where Avance Clinical presented to over 45 Korean biotechs at a clinical trials symposium event. The presentation focused on Avance Clincial’s GlobalReady drug development acceleration solution.
The Avance Clinical team, including CEO Yvonne Lungershausen, and Vice President, Commercial Business Development, Liahna Toy shared drug development options including conducting clinical trials across Korea, Australia, New Zealand, and the United States to support fast tracking clinical trial development programs.
Andy Hu, Business Development Manager for Asia, said Avance Clinical offers two critical solutions for biotechs.
“Avance Clinical in Australia can maximize the 43.5% rebate on clinical trial spend, and in the United States can provide high quality trials following the FDA pathway. Both approaches were received as attractive propositions for biotechs wanting to maximize their data captured and conserve funding,” he said.
Liahna Toy, Vice-President, Commercial Business Development said:
“Our Avance Clinical teams in Australia and the United States offer world-class quality data and cultural alignment for Korean biotech clients designed to make their drug development programs seamless and successful.”
“Avance Clinical’s study data is accepted by all the main regulatory authorities including the MFDS and FDA; and conversely the Therapeutic Goods Administration (TGA) in Australia recognizes data generated in Korea.”
“The Korean biopharma companies we met at KoNECT Korea Conference were outstanding and we are extremely excited to be part of their clinical program as they expand to the United States.”
About Avance Clinical
Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.
Award-winning CRO for Biotechs
Avance Clinical has been recognized for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech’s award, for its continuous exceptional performance.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia and highly qualified sites and networks within the United States. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners.